Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
Eugene Han (Han E), Gyuri Kim (Kim G), Ji-Yeon Lee (Lee JY), Yong-ho Lee (Lee Yh), Beom Seok Kim (Kim BS), Byung-Wan Lee (Lee BW), Bong-Soo Cha (Cha BS), Eun Seok Kang (Kang ES)
Endocrinol Metab. 2017;32(2):274-280.   Published online 2017 Jun 23     DOI: https://doi.org/10.3803/EnM.2017.32.2.274
Citations to this article as recorded by Crossref logo
Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options
Ahmed H. Abdelhafiz
Drugs & Aging.2020; 37(8): 567.     CrossRef
Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane
Pan-Feng Feng, Bo Zhang, Lei Zhao, Qing Fang, Yan Liu, Jun-Nan Wang, Xue-Qi Xu, Hui Xue, Yang Li, Cai-Chuan Yan, Xin Zhao, Bao-Xin Li
Molecular Pharmaceutics.2019; 16(4): 1477.     CrossRef
The problem of safety of lipid-lowering therapy
M V. Zykov
Kardiologiia.2019; 59(5S): 13.     CrossRef
Regional evidence and international recommendations to guide lipid management in Asian patients with type 2 diabetes with special reference to renal dysfunction
Titus WL Lau, Kevin E.K. Tan, Jason C.J. Choo, Tsun-Gun Ng, Subramaniam Tavintharan, Juliana C.N. Chan
Journal of Diabetes.2018; 10(3): 200.     CrossRef
Lipids: a personal view of the past decade
Niki Katsiki, Dimitri P Mikhailidis
Hormones.2018; 17(4): 461.     CrossRef